Virax Biolabs Group Ltd. Class A ( (VRAX) ) has issued an announcement.
On March 5, 2025, Virax Biolabs announced that its management will present at the 19th World Immune Regulation Meeting in Davos, Switzerland, from March 12-15, 2025. The presentation, led by COO Dr. Nigel McCracken, will focus on T cell dysfunction in post-acute infection syndromes. The company will also showcase its immune profiling products and engage with research organizations and potential customers, highlighting its commitment to advancing immunology research and strengthening its industry presence.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases. The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, which is particularly effective in diagnosing and treating post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
YTD Price Performance: -33.48%
Average Trading Volume: 403,212
Technical Sentiment Consensus Rating: Buy
See more insights into VRAX stock on TipRanks’ Stock Analysis page.